Medtronic concludes enrollment in 'extreme risk' study of CoreValve

Medtronic ($MDT) has wrapped up patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The study is enrolling more than 1,500 patients in 45 sites, with approximately two-thirds of patients in the high-risk study. The system is designed to replace diseased aortic valves without open-heart surgery. Medtronic release